H.R. 5197House115th Congress (2017-2019)Passed House

ALTO Act

Introduced March 7, 2018

AI-Generated Summary

Updated April 15, 2026 at 8:39 PM UTC

The ALTO Act directs the Department of Health and Human Services to run a demonstration program that gives grants to hospitals and emergency departments to develop and test pain‑management methods that reduce opioid prescribing. The program focuses on common painful conditions and aims to train staff, provide non‑opioid treatments, and gather data on outcomes, with the goal of informing broader use of such alternatives across the health‑care system.

Key Provisions

  • HHS will award grants to eligible hospitals and emergency departments to create, improve, or study alternative pain‑management protocols that limit opioid use.
  • Grants must target common painful conditions (e.g., kidney stones, sciatica, headaches, fractures) and exclude patients with cancer‑related pain, end‑of‑life care, or complex trauma.
  • Funding can be used for training staff, implementing non‑opioid treatments (including approaches like acupuncture), and providing those alternatives to patients.
  • The Secretary must ensure geographic diversity among grant recipients and provide technical support and a platform for recipients to share best practices.
  • Grant recipients must submit annual reports detailing the protocols used, patient demographics, opioid prescribing data, and outcomes.
  • Within one year after the program ends, HHS must report to Congress on the results and recommend how to expand successful protocols.
  • The program is funded at $10 million per year for fiscal years 2019‑2021.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

13 earlier actions
SenateIntro Referral Latest Action

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

June 13, 2018

View full timeline
HouseIntro Referral

Introduced in House

March 7, 2018

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

March 7, 2018

HouseCommittee

Referred to the Subcommittee on Health.

March 9, 2018

HouseCommittee

Subcommittee Consideration and Mark-up Session Held.

April 25, 2018

HouseCommittee

Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

April 25, 2018

HouseCommittee

Committee Consideration and Mark-up Session Held.

May 9, 2018

HouseCommittee

Ordered to be Reported (Amended) by Voice Vote.

May 9, 2018

HouseFloor

Mr. Walden moved to suspend the rules and pass the bill, as amended.

June 12, 2018 • 5:40 PM

HouseFloor

Considered under suspension of the rules. (consideration: CR H5067-5069)

June 12, 2018 • 5:41 PM

HouseFloor

DEBATE - The House proceeded with forty minutes of debate on H.R. 5197.

June 12, 2018 • 5:41 PM

HouseFloor

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5067-5068)

June 12, 2018 • 5:53 PM

HouseFloor

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5067-5068)

June 12, 2018 • 5:53 PM

HouseFloor

Motion to reconsider laid on the table Agreed to without objection.

June 12, 2018 • 5:53 PM

SenateIntro Referral

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

June 13, 2018

Floor Debate

4 members

What members said about H.R. 5197 on the floor

1 Republican3 Democrats
Greg Walden
Rep. Greg WaldenR-OR-2 · Jun 12, 2018

Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 5197) to direct the Secretary of Health and Human Services to conduct a demonstration program to test alternative pain management…

Bill Pascrell, Jr.
Rep. Bill Pascrell, Jr.D-NJ-9 · Jun 12, 2018

Mr. Speaker, I rise today in support of H.R. 5197, the Alternatives to Opioids, ALTO, in the Emergency Department Act. I would like to thank Chairman Walden and Ranking Member Pallone for their work,…

Sheila Jackson Lee
Rep. Sheila Jackson LeeD-TX-18 · Jun 12, 2018

Mr. Speaker, I rise in strong support of H.R. 5197, the Alternatives to Opioids in the Emergency Department Act, or the ALTO Act. Mr. Speaker, our nation faces an opioid crisis. H.R. 5197, the ALTO…

Sheila Jackson Lee
Rep. Sheila Jackson LeeD-TX-18 · Jul 6, 2018

Mr. Speaker, I rise in strong support of H.R. 5197, the Alternatives to Opioids in the Emergency Department Act, or the ALTO Act. Mr. Speaker, our nation faces an opioid crisis. H.R. 5197, the ALTO…

Frank Pallone, Jr.
Rep. Frank Pallone, Jr.D-NJ-6 · Jun 12, 2018

Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise in support of H.R. 5197, the Alternatives to Opioids in the Emergency Department Act, introduced by my colleague from New…

Bill Text

3 versions available

Reading Mode
Latest
Referred in SenateIssued June 13, 2018

IIB

115th CONGRESS

2d Session

H. R. 5197

IN THE SENATE OF THE UNITED STATES

June 13, 2018

Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions

AN ACT

To direct the Secretary of Health and Human Services to conduct a demonstration program to test alternative pain management protocols to limit the use of opioids in emergency departments.

1.

Short title

This Act may be cited as the Alternatives to Opioids in the Emergency Department Act or the ALTO Act.

2.

Emergency department alternatives to opioids demonstration program

(a)

Demonstration program grants

The Secretary of Health and Human Services (in this section referred to as the Secretary) shall carry out a demonstration program under which the Secretary shall award grants to hospitals and emergency departments, including freestanding emergency departments, to develop, implement, enhance, or study alternative pain management protocols and treatments that limit the use and prescription of opioids in emergency departments.

(b)

Eligibility

To be eligible to receive a grant under subsection (a), a hospital or emergency department shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.

(c)

Geographic diversity

In awarding grants under this section, the Secretary shall seek to ensure geographical diversity among grant recipients.

(d)

Use of funds

Grants under subsection (a) shall be used to—

(1)

target common painful conditions, such as renal colic, sciatica, headaches, musculoskeletal pain, and extremity fractures;

(2)

train providers and other hospital personnel on protocols and the use of treatments that limit the use and prescription of opioids in the emergency department; and

(3)

provide alternatives to opioids to patients with painful conditions, not including patients who present with pain related to cancer, end-of-life symptom palliation, or complex multisystem trauma.

(e)

Consultation

The Secretary shall implement a process for recipients of grants under subsection (a) to consult (in a manner that allows for sharing of evidence-based best practices) with each other and with persons having robust knowledge, including emergency departments and physicians that have successfully deployed alternative pain management protocols, such as non-drug approaches studied through the National Center for Complimentary and Integrative Health including acupuncture that limit the use of opioids. The Secretary shall offer to each recipient of a grant under subsection (a) technical support as necessary.

(f)

Report to the Secretary

Each recipient of a grant under this section shall submit to the Secretary (during the period of such grant) annual reports on the progress of the program funded through the grant. These reports shall include, in accordance with State and Federal statutes and regulations regarding disclosure of patient information—

(1)

a description of and specific information about the alternative pain management protocols employed;

(2)

data on the alternative pain management protocols and treatments employed, including—

(A)

during a baseline period before the program began, as defined by the Secretary;

(B)

at various stages of the program, as determined by the Secretary; and

(C)

the conditions for which the alternative pain management protocols and treatments were employed;

(3)

the success of each specific alternative pain management protocol;

(4)

data on the opioid prescriptions written, including—

(A)

during a baseline period before the program began, as defined by the Secretary;

(B)

at various stages of the program, as determined by the Secretary; and

(C)

the conditions for which the opioids were prescribed;

(5)

the demographic characteristics of patients who were treated with an alternative pain management protocol, including age, sex, race, ethnicity, and insurance status and type;

(6)

data on patients who were eventually prescribed opioids after alternative pain management protocols and treatments were employed; and

(7)

any other information the Secretary deems necessary.

(g)

Report to Congress

Not later than 1 year after completion of the demonstration program under this section, the Secretary shall submit a report to the Congress on the results of the demonstration program and include in the report—

(1)

the number of applications received and the number funded;

(2)

a summary of the reports described in subsection (f), including standardized data; and

(3)

recommendations for broader implementation of pain management protocols that limit the use and prescription of opioids in emergency departments or other areas of the health care delivery system.

(h)

Authorization of appropriations

To carry out this section, there is authorized to be appropriated $10,000,000 for each of fiscal years 2019 through 2021.

Passed the House of Representatives June 12, 2018.

Karen L. Haas,

Clerk